Epsilon Healthcare Limited

EPN.ASX

Health Care

EPN is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest cannabis manufacturing facility in the Southern Hemisphere.

Market Data

Price

$0.024

-0.0%
Market Cap

$9.3M

P/E Ratio

-100000.0x

EPS

$-0.004

Div. Yield

0.00%

52-Week Change

-0.2%

Latest Earnings

Preliminary Final Report

27 February 2026

Revenue
$9.39
+68.0% YoY
NPAT
-$2.05
+62.7% YoY
EPS
$-0.01

Epsilon Healthcare delivered a strong recovery in FY2025, with revenue surging 68% to $9.4M driven by CDMO manufacturing growth and the successful launch of a new Pharmacy division, though the company remains unprofitable with a loss of $2.1M (improving 63% from prior year's $5.5M loss). The turnaround reflects elimination of one-off voluntary administration costs and improved operational discipline, positioning the business for sustainable growth as manufacturing facility utilization increases. Key points: Revenue growth of 68% to $9.4M, driven by strong CDMO segment performance and early success of new Pharmacy division ($1.2M annualized revenue in first year); Net loss improved significantly by 63% to $2.1M from $5.5M prior year, reflecting elimination of one-off voluntary administration costs ($1.2M reduction in non-recurring expenses); Gross margin strong at 61.3% despite COGS increase proportional to revenue growth; underlying cost base reduced by $1.1M+ through operational efficiency

Recent Announcements

27 Feb 2026 Actual Results Positive

Preliminary Final Report

Epsilon Healthcare delivered a strong recovery in FY2025, with revenue surging 68% to $9.4M driven by CDMO manufacturing growth and the successful launch of a new Pharmacy division, though the company remains unprofitable with a loss of $2.1M (improving 63% from prior year's $5.5M loss). The turnaround reflects elimination of one-off voluntary administration costs and improved operational discipline, positioning the business for sustainable growth as manufacturing facility utilization increases. Key points: Revenue growth of 68% to $9.4M, driven by strong CDMO segment performance and early success of new Pharmacy division ($1.2M annualized revenue in first year); Net loss improved significantly by 63% to $2.1M from $5.5M prior year, reflecting elimination of one-off voluntary administration costs ($1.2M reduction in non-recurring expenses); Gross margin strong at 61.3% despite COGS increase proportional to revenue growth; underlying cost base reduced by $1.1M+ through operational efficiency

Get real-time alerts for EPN

Receive AI-powered earnings summaries and instant notifications when Epsilon Healthcare Limited releases results.

Register Free